JP2023551193A - 抗体関連型拒絶反応を処置するための方法 - Google Patents

抗体関連型拒絶反応を処置するための方法 Download PDF

Info

Publication number
JP2023551193A
JP2023551193A JP2023530546A JP2023530546A JP2023551193A JP 2023551193 A JP2023551193 A JP 2023551193A JP 2023530546 A JP2023530546 A JP 2023530546A JP 2023530546 A JP2023530546 A JP 2023530546A JP 2023551193 A JP2023551193 A JP 2023551193A
Authority
JP
Japan
Prior art keywords
inh
administered
dose
doses
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551193A5 (https=
Inventor
ジョン・ロバーツ
マルク・ウグニス
クリスティーネ・フォークト
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2023551193A publication Critical patent/JP2023551193A/ja
Publication of JP2023551193A5 publication Critical patent/JP2023551193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023530546A 2020-11-20 2021-11-18 抗体関連型拒絶反応を処置するための方法 Pending JP2023551193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116405P 2020-11-20 2020-11-20
US63/116,405 2020-11-20
PCT/US2021/059872 WO2022109124A1 (en) 2020-11-20 2021-11-18 Method for treating antibody-mediated rejection

Publications (2)

Publication Number Publication Date
JP2023551193A true JP2023551193A (ja) 2023-12-07
JP2023551193A5 JP2023551193A5 (https=) 2024-11-25

Family

ID=78918649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530546A Pending JP2023551193A (ja) 2020-11-20 2021-11-18 抗体関連型拒絶反応を処置するための方法

Country Status (8)

Country Link
US (1) US20240000908A1 (https=)
EP (1) EP4247416A1 (https=)
JP (1) JP2023551193A (https=)
KR (1) KR20230110563A (https=)
CN (1) CN116568327A (https=)
AU (1) AU2021381360A1 (https=)
CA (1) CA3198740A1 (https=)
WO (1) WO2022109124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067383A1 (zh) * 2023-09-28 2025-04-03 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537380A (ja) * 2013-11-22 2016-12-01 シャイア バイロファーマ インコーポレイテッド 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537380A (ja) * 2013-11-22 2016-12-01 シャイア バイロファーマ インコーポレイテッド 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF TRANSPLANTATION, vol. 16, JPN6025049876, 2016, pages 1596 - 1603, ISSN: 0005749162 *
CSL BEHRING, 1.14.1.3 DRAFT LABELING TEXT BERINERT, C1ESTERASE INHIBITOR (HUMAN) ,[ONLINE], JPN6025049880, December 2019 (2019-12-01), ISSN: 0005749163 *
THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: IN PRACTICE, vol. Volume 8, Issue 3, JPN6025049877, March 2020 (2020-03-01), pages 892 - 900, ISSN: 0005749164 *

Also Published As

Publication number Publication date
AU2021381360A1 (en) 2023-06-22
CN116568327A (zh) 2023-08-08
KR20230110563A (ko) 2023-07-24
EP4247416A1 (en) 2023-09-27
WO2022109124A1 (en) 2022-05-27
CA3198740A1 (en) 2022-05-27
US20240000908A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US6013256A (en) Method of preventing acute rejection following solid organ transplantation
CA2644020C (en) Prolongation of survival of an allograft by inhibiting complement activity
Gallego-Pinazo et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP6620206B2 (ja) 臓器移植患者における抗体媒介性拒絶反応のｃ１−エステラーゼ阻害剤を使用した治療方法
JP2002500648A (ja) 反適応性の免疫応答、特に移植片拒絶を防ぐためのｃｄ４０：ｃｄ１５４結合妨害剤の使用
JP2025502095A5 (https=)
US20080199478A1 (en) Combinations of Immunosupressive Agents for the Treatment or Prevention of Graft Rejections
Myburgh et al. Total lymphoid irradiation in renal transplantation
JP2023551193A (ja) 抗体関連型拒絶反応を処置するための方法
CN116783216A (zh) 用于诱导耐受性的方法和组合物
JP2021505545A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
Moon Overcoming high pre-transplant isoagglutinin titers using high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab without splenectomy in ABO-incompatible living donor liver transplantation: a case report
CN118973600A (zh) 用于脐带血移植后的血细胞恢复的药物组合物
Bernardeschi et al. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study
WO2025207763A1 (en) Method and composition for inducing tolerance of transplanted organ or tissue
Habal et al. Renal allografting in the patient with juvenile diabetes mellitus
INTEREST—PHASE III Pharmaceutical Clinical Trials—Phase Three
Kumar et al. Antilymphocyte Globulin (ALG) infusion in the treatment of acute renal allograft rejection: a prospective study
Adya Management of scleroderma
KUMAR et al. 6. Antilymphocyte Globulin (ALG) infusion in the treatment of acute renal allograft rejection: a prospective study
Kaufman Development and Application of Contemporary Immunosuppression in Human Islet Transplantation
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260309